Figure 1.
Influenza virus and SARS-CoV-2 test-positive and test-negative specimens, including genetic characterisation, by week of specimen collection, Canadian Sentinel Practitioner Surveillance Network, 29 October 2023–13 January 2024
SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
Among eligible patients presenting with acute respiratory illness, the distribution of influenza virus A(H1N1)pdm09 genetic sub-clades and subgroups and SARS-CoV-2 genetic lineages among characterised case viruses are also displayed by week of specimen collection, with an overlayed weekly tally of sequenced case viruses. For influenza A(H1N1)pdm09, noted within a square bracket is an affected antigenic site, and in parentheses are corresponding NextStrain influenza subclade nomenclatures. Genetic characterisation details are appended for influenza A(H1N1)pdm09 in Supplementary Table S2 and for SARS-CoV-2 case viruses in Supplementary Table S3.
